Flu-X aids your immune system in preventing the contraction of the Flu and Common Cold
Confirmed to help prevent the replication of both A & B influenza viruses
Spray 5 times in the mouth, 4 times per day.
Children Over 6 yrs
Spray 4 times in the mouth, 3 times per day.
For best results, spray two doses in the nose as well.
A 160 patient placebo-controlled clinical trial of patients with Viral Respiratory Tract Infection demonstrated an 82.9% recovery rate in the Flu-X group compared to 19.6% in the placebo control group. Further, comparative in-vivo studies on mice confirm the product’s superiority to Interferon, a leading anti-viral pharmaceutical against the influenza virus, offering a protection rate of 55% compared to only 40% for Interferon. In clinical tests Flu-X has also been shown to inhibit the H.Influenza, Aureua Staphylococcus and A-hemolytic Steptococcus bacteria strains, associated with secondary flu-related, respiratory bacterial infections.
Long and short term clinical toxicology studies conducted on the product confirm Flu-X to be safe even at 400 times the recommended human dosage. Additionally, the product has been used by over 1,000 volunteers and has been shown to be safe and highly effective in the prevention and treatment of influenza, by killing and preventing the replication of the Influenza A & B Viruses.
The similarities between SARS-CoV and SARS-CoV-2 are striking, not only in name. The whole genome of SARS-CoV-2 has a 86% similarity with SARS-CoV. Both viruses share high degrees of homology to SARS-like viruses isolated in bats, suggesting that bats are the probable origin of both SARS-CoV and SARS-CoV-2.
Even in terms of disease dynamics there are apparent similarities. The main transmission route is thought to be respiratory droplets, although viral shedding via feces has also been reported for both viruses. The angiotensin-converting enzyme 2 (ACE2), found in the lower respiratory trace of humans, has been identified as the receptor used for cell entry for both SARS-CoV and SARS-CoV-2. To be clear, Flu-X is not proven to address.
Professor D. S. Liu, Ph.D ~ Inventor
Professor Liu has over 40 years experience in molecular biology and virology and graduated as a physician from China’s prestigious China Medical University. He completed his post-graduate degree at the China Academy of Medical Sciences under the supervision of Professor Zhu Jiming, the scientist who isolated the first Asian influenza strain in the world, in the 1950’s. Professor Liu has worked extensively as a virologist with projects for the World Health Organization (WHO), Royal Post Graduate Medical School, U.K., Wellcome Research Laboratories, U.K., and Peninsular Laboratory Inc., in the USA. He has been awarded “National Special Contribution Scientist” by the State Council of China and is a member of the editorial committee of the “China Immunology Journal”. He is also a Scientific Advisor for the anti-cancer drug development at Swiss Debiopharm Research Foundation.